This installation of Ropes & Gray s podcast series
Non-binding Guidance focuses on FDA regulatory
developments in the area of artificial intelligence
( AI ) and machine learning. AI and machine learning
represent a rapidly growing frontier in digital health, with
applications ranging from medical device software used for
diagnostic and triaging applications to drug candidate selection to
clinical trial design and interpretation. In this episode, FDA
regulatory attorneys Kellie Combs, Greg Levine, and Sarah
Blankstein explore the development and uptake of these technologies
in response to the ongoing COVID-19 pandemic, FDA s current
regulatory landscape for these technologies, recent steps FDA has
taken to update its regulatory approach to these tools in
2 Major Digital Health Trends Driven By COVID-19 By
Megan Baca, Kellie Combs and Christine Moundas Law360 is providing free access to its coronavirus coverage to make sure all members of the legal community have accurate information in this time of uncertainty and change. Use the form below to sign up for any of our weekly newsletters. Signing up for any of our section newsletters will opt you in to the weekly Coronavirus briefing.
Sign up for our Compliance newsletter
You must correct or enter the following before you can sign up:
Email (NOTE: Free email domains not supported)
Primary area of interest